|
GB0523539D0
|
|
New use of organic compounds
|
|
SI21221A
|
|
Quickly decomposable tablets
|
|
SI21233A
|
|
High purity crystalline hydrate forms of amlodipine benzensulphonate, methods of their preparation and usage
|
|
EP1492878A1
|
|
Process for the preparation of a desired erythropoietin glyco-isoform profile
|
|
SI21137A
|
|
Derivatives of azaphenyl-alanine
|
|
WO03055475A1
|
|
Controlled release pharmaceutical formulation containing venlafaxine
|
|
SI21102A
|
|
Process for isolation of biologically active granulocyte colony stimulating factor
|
|
SI20875A
|
|
Crystal form of omeprazole
|
|
SI20848A
|
|
Pharmaceutical formulation containing atorvastatin calcium
|
|
SI20814A
|
|
Preparation of amorphous atorvastatin
|
|
SI20720A
|
|
New pharmaceutical preparation in the form of cellulose capsules applicable to derivatives of benzimidazole
|
|
SI20411A
|
|
Watersoluble powders for peroral solution and their use
|
|
SI20425A
|
|
Preparation of amorphous atorvastatin
|
|
CZ2001137A3
|
|
Process for obtaining HMG-CoA reductase inhibitors of high purity
|
|
SI20305A
|
|
Pravastatin sodium salt crystals
|
|
HU0103015A2
|
|
Pharmaceutical suspension formulation comprising amoxycillin, clavulanic acid and cellulose
|
|
SI20246A
|
|
Use of compound n-(2-(2-(1-adamanthancarboxamido)-ethoxy)-acetyl)-l-alanyl-d- isoglutamine in veterinary medicine
|
|
SI20244A
|
|
Melt granulation
|
|
SI20150A
|
|
Directly compressible matrix for controlled release of the daily dose of clarytomicyne
|
|
SI20159A
|
|
New process for the removal of the silyloxy protective group from 4-silyoxy tetrahydro-pyran-2-ons
|
